文献速递肿瘤 PET/CT放射性药物与辐射防护

围手术期PET/CT淋巴显像与荧光实时成像用于早期结肠癌前哨淋巴结定位

Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-02-23

结论提示该技术可术前告知前哨淋巴结数目和位置,但需进一步研究改进和简化。

要点

  • 术前PET/CT淋巴显像可于注射后24小时告知前哨淋巴结数目和位置。
  • 近红外成像可术中识别常规白光下不可见的前哨淋巴结,78%被找到。
  • 位于原发肿瘤附近(<2 cm)的前哨淋巴结术中近红外识别困难。

核心结论

  • 术前PET/CT淋巴显像有潜力告知外科医生早期结肠癌患者前哨淋巴结的数目和位置。
  • 联合近红外成像可术中识别常规白光成像不可见的前哨淋巴结。
  • 作者推荐术前约24小时注射后行淋巴显像、术中实时近红外成像及术后标本扫描。
  • 需进一步研究改进和简化该技术。

研究设计与样本

  • submucosal注射[89Zr]Zr-Nanocoll后行三次术前PET/CT扫描及额外的标本离体扫描。
  • 所有前哨淋巴结及其他淋巴结均行广泛病理检查以寻找转移。
  • 前哨淋巴结定义为术前PET/CT可见且标本PET/CT识别并经组织病理学证实的淋巴结。

主要发现

  • 8例两种示踪剂均成功注射的患者中7例共获取27枚前哨淋巴结。
  • 1例患者术前未指定前哨淋巴结。
  • 2例患者因针头位置不正确导致[89Zr]Zr-Nanocoll注射失败。

关键数值与推荐

  • 前哨淋巴结定义:术前PET/CT可见且标本PET/CT识别并经组织病理学证实的淋巴结。

临床怎么用

  • 早期结肠癌可考虑术前约24小时注射[89Zr]Zr-Nanocoll行PET/CT淋巴显像以告知前哨淋巴结数目和位置。
  • 术中联合近红外成像可识别常规白光下不可见的前哨淋巴结。
  • 术后行标本PET/CT扫描并结合术中实时近红外成像。
  • 位于原发肿瘤附近(<2 cm)的前哨淋巴结术中近红外识别困难,需注意。

局限性

  • 2例因针头位置不正确导致[89Zr]Zr-Nanocoll注射失败。
  • 1例患者术前未指定前哨淋巴结。
  • 术中近红外成像未找到的6枚前哨淋巴结均位于肿瘤附近。
  • 作者指出需进一步研究改进和简化该技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Using current optical imaging techniques and gamma imaging modalities, perioperative sentinel lymph node (SLN) identification in colon cancer can be difficult when the SLN is located near the primary tumour or beneath a thick layer of (fat) tissue. Sentinel lymph node mapping using PET/CT lymphoscintigraphy combined with real-time visualization of the SLN using near-infrared imaging has shown promising results in several types of cancer and may facilitate the successful identification of the number and location of the SLN in early colon cancer. METHODS: Clinical feasibility of PET/CT lymphoscintigraphy using preoperative endoscopically injected [89Zr]Zr-Nanocoll and intraoperative injection of the near-infrared (NIR) tracer Indocyanine Green (ICG) was evaluated in ten early colon cancer patients. Three preoperative PET/CT scans and an additional ex vivo scan of the specimen were performed after submucosal injection of [89Zr]Zr-Nanocoll. All SLNs and other lymph nodes underwent extensive pathological examination for metastases. A histopathological proven lymph node visible at preoperative PET/CT and identified at PET/CT of the specimen was defined as SLN. RESULTS: A total of 27 SLNs were harvested in seven out of eight patients with successful injection of both tracers. In one patient no SLNs were assigned preoperatively. In two patients injection of [89Zr]Zr-Nanocoll failed due to incorrect needle positioning. Twenty-one (78%) SLNs were found intraoperatively using NIR-imaging. Eleven of the 27 (41%) SLNs were located near the primary tumour (< 2 cm). Those six SLNs not found intraoperatively with NIR-imaging were all located close to the tumour. In all seven patients at least one SLN could be assigned at preoperative imaging 24 h after tracer administration. One SLN contained metastases detected by immunohistochemistry. No metastases were found in the non-SLNs. CONCLUSIONS: This study shows the potential of preoperative PET/CT lymphoscintigraphy to inform the surgeon about the number and location of SLNs in patients with early colon cancer. The additional use of NIR-imaging allows for intraoperative identification of these SLNs which are invisible with conventional white light imaging. Further research is necessary to improve and simplify the technique. We recommend perioperative SLN identification using a preoperative lymphoscintigraphy scan just before surgery approximately 24 h after injection. Additionally a postoperative scan of the specimen combined with intraoperative real-time NIR-imaging should be performed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ankersmit M, Hoekstra OS, van Lingen A, et al. Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 30798428. doi:10.1007/s00259-019-04284-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。